These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7229622)

  • 1. A vaccine prepared from the 22 nm particles of surface hepatitis B antigen (HBsAg).
    Karelin VP; Babaeva EE; Gubenko EF; Kaulen DK; Zhdanov VM
    J Med Virol; 1980; 5(4):331-41. PubMed ID: 7229622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experiments for the development of a hepatitis B vaccine: immunogenicity of HBsAg in guinea pigs (author's transl)].
    Stamm B; Gerlich W; Thomssen R
    Med Microbiol Immunol; 1979 May; 167(2):83-97. PubMed ID: 572908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recombinant Oka varicella vaccine as a live hepatitis B virus vaccine].
    Shiraki K; Takahara T
    Nihon Rinsho; 1993 Jan; 51(1):241-7. PubMed ID: 8381884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New approaches to obtaining vaccines for preventing serum hepatitis type B].
    Karelin VP; Gubenko EF; Zhdanov VM
    Vopr Virusol; 1980; (6):682-8. PubMed ID: 6164163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemical structure of the hepatitis B surface antigen vaccine--I. Treatment of immobilized HBsAg by dissociation agents with or without enzymatic digestion and identification of polypeptides by protein blotting.
    Pillot J; Petit MA
    Mol Immunol; 1984 Jan; 21(1):53-60. PubMed ID: 6423972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions.
    Steward MW; Sisley BM; Stanley C; Brown SE; Howard CR
    Clin Exp Immunol; 1988 Jan; 71(1):19-25. PubMed ID: 3349646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of the immunogenic activity of hepatitis B surface antigen (HBsAg) and HBsAg polypeptides.
    Sanchez Y; Ionescu-Matiu I; Melnick JL; Dreesman GR
    J Med Virol; 1983; 11(2):115-24. PubMed ID: 6842190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic hepatitis B surface antigen peptide vaccine.
    Dreesman GR; Sparrow JT; Frenchick PJ; Kennedy RC
    Adv Exp Med Biol; 1985; 185():129-37. PubMed ID: 2416196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemical structure of the hepatitis B surface antigen vaccine--II. Analysis of antibody responses in human sera against the envelope proteins.
    Petit MA; Maillard P; Capel F; Pillot J
    Mol Immunol; 1986 May; 23(5):511-23. PubMed ID: 3748012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection.
    Du DW; Jia ZS; Li GY; Zhou YY
    World J Gastroenterol; 2003 Jan; 9(1):108-11. PubMed ID: 12508362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutated epitopes of hepatitis B surface antigen fused to the core antigen of the virus induce antibodies that react with the native surface antigen.
    Shiau AL; Murray K
    J Med Virol; 1997 Mar; 51(3):159-66. PubMed ID: 9139078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type B hepatitis: a review of current prospects for a safe and effective vaccine.
    McAuliffe VJ; Purcell RH; Gerin JL
    Rev Infect Dis; 1980; 2(3):470-92. PubMed ID: 6997970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
    Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
    Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micelles.
    Tabor E; Howard CR; Skelly J; Snoy P; Goudeau A; Zuckerman AJ; Gerety RJ
    J Med Virol; 1982; 10(1):65-74. PubMed ID: 7130967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis B vaccination - before a breakthrough?].
    Grob PJ
    Schweiz Med Wochenschr; 1981 Aug; 111(31-32):1146-53. PubMed ID: 7025194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid substitutions Q129N and T131N/M133T in hepatitis B surface antigen (HBsAg) interfere with the immunogenicity of the corresponding HBsAg or viral replication ability.
    Kang Y; Li F; Guo H; Yang S; Zhang Y; Zhu H; Wang J; Mao R; Qin Y; Xu J; Chen X; Wu C; Zhang J
    Virus Res; 2018 Sep; 257():33-39. PubMed ID: 30179704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubular forms of hepatitis B surface antigen bind with the nucleus of 22-nm spherical HBsAg particles.
    Mishiro S; Imai M; Gotanda T; Takahashi K; Sano T; Yoshizawa H; Miyakawa Y; Mayumi M
    J Med Virol; 1981; 6(4):269-78. PubMed ID: 7241094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.
    del Valle JR; Devaux P; Hodge G; Wegner NJ; McChesney MB; Cattaneo R
    J Virol; 2007 Oct; 81(19):10597-605. PubMed ID: 17634218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen mimicry by anti-idiotype antibodies that recognize a common anti-hepatitis B surface antigen idiotype.
    Kennedy RC; Dreesman GR
    Adv Exp Med Biol; 1985; 185():139-47. PubMed ID: 2416197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.
    Desombere I; Willems A; Gijbels Y; Leroux-Roels G
    J Virol; 2006 Apr; 80(7):3506-14. PubMed ID: 16537618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.